John Paul Mathias
32Patents
10h-index
66Co-inventors
78Inventor score
Filing activity: Sep 29, 1999 → Jun 28, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6916927B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | Chemistry; Metallurgy | 105 | Expired |
| US10208053B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | Human Necessities | 30 | Active |
| US10131670B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | Human Necessities | 26 | Active |
| US6670366B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | Chemistry; Metallurgy | 25 | Expired |
| US6458951B2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | Chemistry; Metallurgy | 25 | Expired |
| US6333330A | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | Chemistry; Metallurgy | 24 | Expired |
| US9879022B2 | Bicyclic-fused heteroaryl or aryl compounds | Chemistry; Metallurgy | 18 | Active |
| US9458168B2 | Bicyclic-fused heteroaryl or aryl compounds | Chemistry; Metallurgy | 15 | Active |
| US6251904A | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | Chemistry; Metallurgy | 13 | Expired |
| US6407114B1 | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | Human Necessities | 12 | Expired |
| US7511057B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | Human Necessities | 10 | Active |
| US7153870B2 | Nicotinamide derivatives useful as PDE4 inhibitors | Chemistry; Metallurgy | 7 | Expired |
| US6723719B1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction | Chemistry; Metallurgy | 6 | Expired |
| US6677335B1 | Pharmaceutically active compounds | Chemistry; Metallurgy | 4 | Expired |
| US10329302B2 | Bicyclic-fused heteroaryl or aryl compounds | Chemistry; Metallurgy | 3 | Active |
| US6949573B2 | Nicotinamide derivatives useful as PDE4 inhibitors | Emerging Cross-Sectional Technologies | 3 | Expired |
| US10308615B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | Chemistry; Metallurgy | 3 | Active |
| US6936619B2 | Quinazolinone compounds useful in therapy | Chemistry; Metallurgy | 3 | Expired |
| US10174000B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | Chemistry; Metallurgy | 3 | Active |
| US7557121B2 | Tetrahydronaphthyridine derivatives | Human Necessities | 2 | Expired |
| US11702424B2 | Bicyclic-fused heteroaryl or aryl compounds | Chemistry; Metallurgy | 2 | Active |
| US10793579B2 | Bicyclic-fused heteroaryl or aryl compounds | Chemistry; Metallurgy | 2 | Active |
| US7060717B2 | Nicotinamide derivatives useful as PDE4 inhibitors | Emerging Cross-Sectional Technologies | 1 | Expired |
| US10316018B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | Chemistry; Metallurgy | 1 | Active |
| US7176311B2 | Process for preparing pharmaceutically active compounds | Chemistry; Metallurgy | 1 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.